{
  "study_metadata": {
    "design": "RCT",
    "species": "Homo sapiens",
    "n_total": 32,
    "country": "United States",
    "setting": "outpatient",
    "population": "overweight older adults",
    "inclusion_key": "overweight adults aged 65 and older",
    "exclusion_key": "active cancer, psychiatric illness, etc.",
    "mean_age": 73.0,
    "female_pct": null,
    "diabetes_status": null,
    "primary_outcome": "FPG"
  },
  "intervention": {
    "agent": "resveratrol",
    "form": "capsule",
    "dose_mg_per_day": null,
    "duration_weeks": 12.0,
    "cointerventions": null
  },
  "comparison": {
    "type": "placebo",
    "description": "placebo capsule"
  },
  "arms": [
    {
      "name": "placebo",
      "n": null,
      "dose_mg_per_day": null,
      "duration_weeks": 12.0
    },
    {
      "name": "resveratrol",
      "n": null,
      "dose_mg_per_day": 300.0,
      "duration_weeks": 12.0
    },
    {
      "name": "resveratrol",
      "n": null,
      "dose_mg_per_day": 1000.0,
      "duration_weeks": 12.0
    }
  ],
  "outcomes_raw": [
    {
      "name": "FPG",
      "timepoint_weeks": 12.0,
      "arm_name": "resveratrol",
      "baseline_mean": null,
      "baseline_sd": null,
      "followup_mean": null,
      "followup_sd": null,
      "change_mean": null,
      "change_sd": null,
      "units": null,
      "notes": "significantly lower vs placebo"
    }
  ],
  "effects_by_outcome": [
    {
      "name": "FPG",
      "type": null,
      "timepoint_weeks": 12.0,
      "estimate": null,
      "ci_low": null,
      "ci_high": null,
      "p_value": null,
      "adjusted": "false",
      "model_notes": null
    }
  ],
  "risk_of_bias": {
    "randomization_process": null,
    "deviations_from_intended": null,
    "missing_outcome_data": null,
    "measurement_of_outcome": null,
    "selection_of_reported_result": null,
    "overall": null
  },
  "effect": {
    "type": null,
    "estimate": null,
    "ci_low": null,
    "ci_high": null,
    "p_value": null
  },
  "where_found": [
    {
      "section": "abstract",
      "page": null
    },
    {
      "section": "methods",
      "page": null
    },
    {
      "section": "results",
      "page": null
    }
  ],
  "evidence": [
    {
      "section": "abstract",
      "page": null,
      "snippet": "We conducted a double-blind, randomized, placebo-controlled trial to examine the safety and metabolic outcomes in 32 overweight, older adults (mean age, 73 Â± 7 years). Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300 mg/day), and (3) high dose resveratrol (1000 mg/day)."
    },
    {
      "section": "results",
      "page": null,
      "snippet": "Compared to placebo, glucose levels were significantly lower at post-treatment among participants randomized to both resveratrol conditions, with and without adjustment for the corresponding baseline values (ps < 0.05)."
    },
    {
      "section": "methods",
      "page": null,
      "snippet": "Both resveratrol and placebo were orally ingested in capsule form twice daily for 90 days."
    }
  ],
  "missing_fields": [
    "study_metadata.inclusion_key",
    "study_metadata.exclusion_key",
    "study_metadata.female_pct",
    "study_metadata.diabetes_status",
    "intervention.dose_mg_per_day",
    "outcomes_raw.baseline_mean",
    "outcomes_raw.baseline_sd",
    "outcomes_raw.followup_mean",
    "outcomes_raw.followup_sd",
    "outcomes_raw.change_mean",
    "outcomes_raw.change_sd",
    "outcomes_raw.units",
    "effects_by_outcome.estimate",
    "effects_by_outcome.ci_low",
    "effects_by_outcome.ci_high",
    "effects_by_outcome.p_value",
    "risk_of_bias.randomization_process",
    "risk_of_bias.deviations_from_intended",
    "risk_of_bias.missing_outcome_data",
    "risk_of_bias.measurement_of_outcome",
    "risk_of_bias.selection_of_reported_result",
    "risk_of_bias.overall"
  ],
  "confidence": 0.6,
  "comment": "Limited numeric data",
  "comment_detailed": "I searched the abstract, methods, and results sections for study design, population, intervention details, and outcome data. The study is a double-blind, randomized, placebo-controlled trial with 32 overweight older adults in the USA. Intervention was oral resveratrol capsules at 300 mg/day or 1000 mg/day for 90 days. Primary outcome was fasting plasma glucose, reported as significantly lower versus placebo, but no numeric values or effect sizes were provided. Consequently, many numeric fields (means, SDs, effect estimates, CIs) are unknown. Risk of bias details were not reported. Additional information such as full tables or supplementary data would provide the missing statistics. "
}